DailySand tracks clinical safety across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where clinical safety appears in today's cross-sector intelligence briefing.
1 item across 1 digest
A weight loss drug maker's stock fell 23% after new safety data raised investor concerns despite the experimental drug meeting primary efficacy targets. Adverse side effect profiles can eliminate commercial viability and investor returns even when clinical efficacy is demonstrated.
Read original →
DailySand